Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHAPAS-5: Novel Treatment Regimens in Children and Adolescents With HIV in Africa
NCT07792096Phase 3
Key facts
- Status
- Not yet recruiting
- Start
- Nov 2026
- Primary completion
- Jun 2029
- Sponsor
- University College London
- Conditions
- human immunodeficiency virus infection (HIV)
01
Overview
Phase 3, randomised, open-label trial of dolutegravir, abacavir, lamivudine, tenofovir alafenamide, emtricitabine and 2 more in human immunodeficiency virus infection (HIV) (7 arms), sponsored by University College London. Primary endpoint: Proportion of participants alive with HIV Viral Load <400 copies/mL at 48 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Design
7 arms- Study design
- RandomizedOpen-label
ART Naïve DTG/ABC/3TC
ART Naïve participants receiving dolutegravir, abacavir, lamivudine
ART Naïve DTG/TAF/FTC
ART Naïve participants receiving dolutegravir, tenofovir alafenamide, emtricitabine
ART Naïve DTG/3TC
ART Naïve participants receiving dolutegravir, lamivudine
ART Experienced DTG/ABC/3TC
ART Experienced participants receiving dolutegravir, abacavir, lamivudine
ART Experienced DTG/TAF/FTC
ART Experienced participants receiving dolutegravir, tenofovir alafenamide, emtricitabine
ART Experienced DRV/r /ABC/3TC
ART Experienced participants receiving darunavir, ritonavir, abacavir, lamivudine
1 more in the full profile.
03
Who it enrols
Children and adolescents aged 4 weeks to <15 years, weighing 3 to <30kg, with confirmed HIV infection, either ART-naive or ART-experienced on DTG-based ART with unsuppressed viral load.
04
Endpoints
Primary
Proportion of participants alive with HIV Viral Load <400 copies/mL
Secondary
Proportion of participants alive with HIV Viral Load <1000 copies/mL
Proportion of participants with cross-sectional HIV Viral Load ≥50, ≥400, and ≥1000 copies/mL
Proportion of participants with emergent drug resistance
Time to first serious adverse events (SAEs), grade ≥3 adverse events (AEs) and ART-modifying events of any grade
Time to first new or recurrent WHO 3/4 events, or death
Change in CD4 count and CD4 percentage
Change in weight and BMI-for-age
Beyond the preview
Go deeper on NCT07792096.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07792096.